Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder

Autism Spectrum Disorder Clinical Trial

Official title: Neuromodulation for Depression in Autism Spectrum Disorder

Status Recruiting

Clinical Trial Summary

This study will assess clinical and behavioral measures along with electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single intermittent Theta Burst Stimulation (iTBS) session to provide preliminary insight into the potential of TMS as an intervention for depression in individuals with Autism Spectrum Disorder (ASD).

Clinical Trial Description

Participants will complete two separate sessions, approximately one week apart, with each session including: 1) a baseline assessment of neuropsychological, cognitive and behavioral function, 2) neural and visual attentional social response (EEG/ET paradigm), 3) a single iTBS session or sham stimulation to the left DLPFC, and 4) poststimulation assessment of neural and visual attentional social response (EEG/ET paradigm). The order of active stimulation versus sham will be randomized such that half of the participants in each group get the sham stimulation during the first session and half will get active stimulation in the first session then crossover. EEG and eye-tracking will take approximately 60-minutes and will be collected pre-and-post TMS administration. ;

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autistic Disorder
• Child Development Disorders, Pervasive

• NCT number: NCT06142955
• Study type: Interventional
• Source: Yale University
• Contact: Sherab Tsheringla, MD
• Phone: 2032158046
• Email: sherab.tsheringla@yale.edu
• Status: Recruiting
• Phase: N/A
• Start date: April 30, 2024
• Completion date: December 2026